Source link : https://www.newshealth.biz/health-news/acoramidis-snags-fda-approval-for-attr-cardiomyopathy/
Acoramidis (Attruby) gained FDA approval for treating wild-type or variant transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM), BridgeBio Pharma announced. Offering patients near-complete TTR stabilization in an oral tablet, acoramidis is indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM (also known as cardiac ATTR amyloidosis), a rare but increasingly recognized cause of heart […]
Author : News Health
Publish date : 2024-11-25 18:10:33
Copyright for syndicated content belongs to the linked Source.